bioAffinity Technologies, Inc. (BIAF) News
Follow bioAffinity Technologies, Inc. (BIAF) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
bioAffinity Technologies Q3 Revenue Falls on Lower Reimbursement
EQUITY | Nov 06, 2026, 10:39 PM UTC
M
bioAffinity Technologies Reports Q3 2026 Revenue of About $1.1 Million
The company reported a net loss of $5.3 million. Year-to-date testing revenue rose 79% to about $1.1 million, and CyPath Lung test sales doubled versus the first nine months of 2025.
EQUITY | Nov 06, 2026, 10:33 PM UTC
L
bioAffinity debuts federal distribution of CyPath Lung with AvMEDICAL to VA leaders at NAVREF
bioAffinity delivered the first joint exhibition of CyPath Lung under its new federal distribution agreement with AvMEDICAL to over 300 VA physicians and healthcare leaders.Key Highlights:Original SEC Filing: bioAffinity
REGULATION | Sep 30, 2026, 12:33 PM UTC
L
bioAffinity Technologies, Inc. (BIAF) Signs Federal Distribution Deal for CyPath Lung
bioAffinity Technologies entered a nationwide federal healthcare distribution agreement with AvMEDICAL to expand government and agency access to its noninvasive CyPath Lung test, with initial outreach at NAVREF and GO2 c
NEWS | Sep 30, 2026, 12:00 PM UTC
L
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, is taking significant steps toward bringing
NEWS | Sep 30, 2026, 12:00 PM UTC
L
BIAF - bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
BIAF - bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
NEWS | Sep 17, 2026, 12:03 PM UTC
L
bioAffinity Technologies regains Nasdaq compliance; shares surge
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
EQUITY | Sep 09, 2026, 01:01 PM UTC
L
bioAffinity Technologies regains Nasdaq compliance after bid-price recovery
bioAffinity Technologies said it regained Nasdaq minimum $1.00 bid-price compliance and will remain listed on the Nasdaq Capital Market.
REGULATION | Sep 09, 2026, 12:33 PM UTC
L
bioAffinity Technologies regains Nasdaq listing compliance
bioAffinity Technologies, Inc. announced it received written notice from Nasdaq Stock Market LLC stating the company has regained compliance with Nasdaq listing requirements.
EQUITY | Sep 09, 2026, 12:01 PM UTC
L
bioAffinity Technologies to present corporate update at H.C. Wainwright conference
bioAffinity Technologies will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference. The company reports ~600,736 shares outstanding and an aggregate market value of about $5.9 millio
REGULATION | Sep 03, 2026, 09:05 PM UTC
L
bioAffinity Technologies CEO Maria Zannes to present at H.C. Wainwright conference
bioAffinity Technologies, Inc. said President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 08:30 PM UTC
L
6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More
BEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies, which is explorin
EQUITY | Sep 02, 2026, 02:56 AM UTC
L
bioAffinity Technologies advances CyPath Lung for post-treatment surveillance
bioAffinity Technologies said it is advancing CyPath Lung as a noninvasive surveillance option for lung cancer patients after curative-intent treatment.
REGULATION | Sep 01, 2026, 08:44 PM UTC
L
bioAffinity advances CyPath Lung test for lung cancer survivor surveillance
bioAffinity Technologies said it is advancing the potential application of its CyPath Lung test for surveillance of lung cancer survivors.
EQUITY | Sep 01, 2026, 12:00 PM UTC
M
Several stocks begin reverse splits Monday Aug. 24
BIAF, BRCC, INCR, VCIG, GRML, GAME and SKYE are listed for reverse stock splits on Monday Aug. 24, with ratios ranging from 1-for-5 to 1-for-50.
EQUITY | Aug 24, 2026, 09:05 AM UTC
M
Multiple stocks set reverse splits for Monday Aug. 24
BIAF, BRCC, INCR, VCIG, GRML, GAME and SKYE are listed for reverse stock splits effective Monday Aug. 24, with ratios ranging from 1-for-5 to 1-for-50.
EQUITY | Aug 23, 2026, 11:52 AM UTC
L
bioAffinity Technologies sets 1-for-15 reverse stock split
bioAffinity Technologies (BIAF) says its 1-for-15 reverse stock split is effective at the open of trading on August 24, 2026.
REGULATION | Aug 20, 2026, 12:00 PM UTC
M
XOS jumps after securing U.S. Air Force contract
XOS rises 120% after securing a U.S. Air Force contract, while the feed also flags PFSA, WETO, SGLY, TRUG, BIAF, SXTC and EJH as small-cap upside movers.
MNA | Aug 18, 2026, 12:20 PM UTC
M
bioAffinity Technologies prices $4M ATM private placement with warrants
bioAffinity Technologies (BIAF) prices a ~$4.0M-at-gross private placement at-the-market selling 8.46M shares (or pre-funded warrants) plus warrants for up to 16.9M more shares, with warrants struck at $0.4727.
EQUITY | Aug 13, 2026, 01:12 PM UTC
L
BIAF bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early
BIAF bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
EQUITY | Jul 27, 2026, 12:08 PM UTC
H
BIAF: Positive Preclinical Findings
BIAF bioAffinity Technologies reports positive preclinical findings showing proprietary gene silencing technology is selectively cytotoxic to squamous skin cancer cells without harming healthy cells
EQUITY | Jun 22, 2026, 12:00 PM UTC
L
BIAF Raises $3.2M
bioAffinity Technologies announces closing of $3.2 million offering
EQUITY | Jun 18, 2026, 05:19 PM UTC